Omexa Formulary to Invest ₹95 Crore in New Monoclonal Antibody Manufacturing Unit in Tamil Nadu.

Tindivanam, Tamil Nadu , New Monoclonal Antibody Manufacturing Unit in Tamil Nadu : Omexa Formulary has announced plans to establish a state-of-the-art manufacturing facility for monoclonal antibodies and formulation products near Tindivanam, Tamil Nadu. With a proposed investment of ₹95 crore, this project highlights Omexa’s commitment to bolstering India’s position as a global leader in biological products.


Key Details of the Project

1. Strategic Location and Investment

  • Location: The facility will be developed on a 4-acre plot within the TANSIDCO Industrial Park in Pellakuppam Village, Villupuram district, approximately 130 km south of Chennai.
  • Investment: ₹95 crore allocated to build a high-tech production facility catering to domestic and international markets.

2. Production Capabilities

  • Annual capacity: 520 kg of monoclonal antibodies and 1,64,000 units of formulation products per month.
  • Products: The facility will produce 30 monoclonal antibody products and two key formulation types, including prefilled syringes, vials, and lyophilised vials.

3. Employment Generation

  • The project will create employment for 120 individuals, fostering economic growth and local development.

Significance of the Project

Boosting India’s Biologics Industry

The manufacturing unit aligns with India’s vision to become a global supplier of biologics. Leveraging its expertise in fermentation technology, Omexa Formulary plans to produce a range of generic biologics, monoclonal antibodies, and therapeutic proteins, meeting the growing demand for these critical products.

Addressing Market Demand

Monoclonal antibodies are vital in treating various diseases, including cancers, autoimmune disorders, and infectious diseases. This facility will enhance access to affordable, high-quality biologics for both domestic and international markets.

Economic and Social Impact

The investment supports Tamil Nadu’s industrial growth, contributes to India’s bio-economy, and promotes local employment in a high-skill sector.


Omexa’s Competitive Advantage

  1. Advanced Technology: The facility will utilize cutting-edge fermentation technology to ensure consistent quality and efficiency.
  2. Export Potential: With a focus on international markets, Omexa aims to position India as a reliable supplier of monoclonal antibodies.
  3. Comprehensive Product Range: The production of prefilled syringes and lyophilised vials complements the monoclonal antibody offerings, catering to diverse medical needs.

India’s Growing Role in Biopharmaceuticals

India is emerging as a global hub for biopharmaceutical production, with increasing investments in biologics and biosimilars. Omexa’s investment underscores the country’s progress in:

  • Expanding biopharma infrastructure.
  • Supporting innovation in therapeutic solutions.
  • Enhancing the global supply chain for biologics.

FAQs : New Monoclonal Antibody Manufacturing Unit in Tamil Nadu.

Q1: Where is the facility located?

The manufacturing unit will be set up in TANSIDCO Industrial Park, Pellakuppam Village, Tindivanam Taluk, Villupuram district, Tamil Nadu.

Q2: What products will Omexa manufacture?

The facility will produce 30 monoclonal antibody products and formulation products such as prefilled syringes, vials, and lyophilised vials.

Q3: What is the production capacity of the facility?

The facility will have an annual capacity of 520 kg of monoclonal antibodies and 1,64,000 units of formulation products per month.

Q4: How will this project impact employment?

The project is expected to generate 120 job opportunities, contributing to the local economy.

Q5: Why is this project significant for India?

The project supports India’s goal to become a global supplier of biologics, addresses the rising demand for monoclonal antibodies, and enhances the country’s bio-economy.



Scroll to Top